Reducing bias in the assessment of treatment effectiveness: Androgen deprivation therapy for prostate cancer

Medical Care

Volumn 50, Issue 5, 2012, Pages 374-380

  Kuo, Yong Fang ^a   Montie, James E ^b   Shahinian, Vahakn B ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

androgen deprivation therapy; comparative effectiveness research; instrumental variable analysis; prostate cancer

Indexed keywords

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; RADIATION; REGRESSION ANALYSIS; TREATMENT OUTCOME; UROLOGIST;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BIAS (EPIDEMIOLOGY); COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; DATABASES, FACTUAL; HUMANS; MALE; MEDICARE; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; SEER PROGRAM; SOCIOECONOMIC FACTORS; TIME FACTORS; UNITED STATES;

EID: 84861611414     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e318245a086     Document Type: Article

References (37)

1. Lohr K. Comparative effectiveness research methods: symposium overview and summary. Med Care. 2010;48:S3-S6.
2. Grimes DA, Schulz KF. Bias and causal association in observational research. Lancet. 2002;359:248-252. (Pubitemid 34113828)
3. Brookhart MA, Sturmer T, Glynn RJ, et al. Confounding control in healthcare database research-challenges and potential approaches. Med Care. 2010;48:S114-S120.
4. Giordano SH, Kuo YF, Duan Z, et al. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008;112:2456-2466.
5. Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias-effect of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297:278-285. (Pubitemid 46143305)
6. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29:722-729. (Pubitemid 30612241)
7. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17-34. (Pubitemid 28279922)
8. Landrum MB, Ayanian JZ. Causal effect of ambulatory specialty care on mortality following myocardial infarction: a comparison of propensity score and instrumental variable analyses. Health Serv Outcomes Res Methodol. 2001;2:221-245.
9. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173-181. (Pubitemid 351969301)
10. Brookhart MA, Wang PS, Solomon DH, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17:268-275.
11. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary artery bypass grafting and risk of death. N Engl J Med. 2008;358: 771-783. (Pubitemid 351284455)
12. Hardley J, Polsky D, Mandelblatt JD, et al. OPTIONS Research Team. An exploratory instrumental variable analysis of the outcomes of localized breast cancer treatments in a Medicare population. Health Econ. 2003;12:171-186. (Pubitemid 36322102)
13. Kahn JM, Ten Have TR, Iwashyna TJ. The relationship between hospital volume and mortality in mechanical ventilation: an instrumental variable analysis. Health Serv Res. 2009;44:862-879.
14. Rassen JA, Schneeweiss S, Glynn RJ, et al. Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. Am J Epidemiol. 2009;169:273-284.
15. Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment benefits for elderly: the effect of competing risk. Ann Intern Med. 1996;124: 577-584. (Pubitemid 26085060)
16. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002;60:201-208. (Pubitemid 34831758)
17. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61:32-38. (Pubitemid 36349540)
18. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352: 154-164. (Pubitemid 40096612)
19. Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615-1624. (Pubitemid 40490022)
20. Shahinian VB, Kuo YF, Freeman JL, et al. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98:839-845. (Pubitemid 43932049)
21. Wong YN, Freedland SJ, Egleston B, et al. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol. 2009;56:609-616.
22. Lu-Yao G, Moore DF, Oleynick J, et al. Use of hormonal therapy in men with metastatic prostate cancer. J Urol. 2006;176:526-531. (Pubitemid 43927882)
23. Holmes L, Chan W, Ziang Z, et al. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated with locoregional prostate cancer. Prostate Cancer Prostatic Dis. 2007;10: 388-395. (Pubitemid 350238090)
24. Shahinian VB, Kuo YF, Freeman JL, et al. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol. 2007;25:5359-5365. (Pubitemid 350232210)
25. Charlson ME, Pompie P, Ales KL, et al. A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1998;40:373-383.
26. Klabunde C, Potosky A, Legler J, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53: 1258-1267. (Pubitemid 32007842)
27. Agresti A. Categorical Data Analysis. 2nd ed. New York, NY: John Wiley & Sons, Inc; 2002.
28. Cameron AC, Trivedi PA. Microeconometric Using STATA. College Station, TX: StataCorp; 2009.
29. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109-2123. (Pubitemid 38968032)
30. Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol. 2004;22:4109-4118. (Pubitemid 41185180)
31. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol. 1997;79:235-246.
32. Hadley J, Yabroff KR, Barrett MJ, et al. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustment for confounding in observational data. J Natl Cancer Inst. 2010;102:1780-1793.
33. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc. 1996;91:444-455. (Pubitemid 126412813)
34. Laufman L. Primary androgen deprivation therapy in men with prostate cancer. JAMA. 2009;301:35. Letter.
35. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen deprivation therapy for prostate cancer. N Engl J Med. 2010;363:1822-1832.
36. Harris KM, Remler DK. Who is the marginal patient? Understanding instrumental variables estimates of treatment effects. Health Serv Res. 1998;33:1337-1360. (Pubitemid 29006391)
37. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer-a randomized controlled trial. JAMA. 2004;292:821-827. (Pubitemid 39079668)